Patent intelligence · US
US 10006052
Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof
Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof
Patent details — US 10006052
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 26, 2018
- Expiration
- Jun 21, 2038
- Applicant
- PRECISION GENOME ENGINEERING, INC.
- Claims
- 14
- CPC classes
- A61K, A61K38/465, A61K40/11, A61K40/46
Quick answer
US 10006052 (Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof) is held by PRECISION GENOME ENGINEERING, INC.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION GENOME ENGINEERING, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/465, A61K40/11, A61K40/46, A61P, A61P31/00
More from PRECISION GENOME ENGINEERING, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 10006052?
US 10006052 (Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof) is held by PRECISION GENOME ENGINEERING, INC.. Status: granted. Granted Jun 26, 2018. Expires Jun 21, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10006052?
PRECISION GENOME ENGINEERING, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 10006052 expire?
Our index shows an expiration date of Jun 21, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.